MAbs can be created by the Fast-MAb™ platform against antigens provided by clients or in the case of human proteins, these can be recombinantly produced in-house. Anti-human antibodies can be validated to the point of becoming HighSpec™.
Hybridoma development order form: PDF Version
Electronic Version
Comming Soon
Client and proprietary MAbs can be produced from ascites.
Ascites production form: PDF Version
Electronic Version
Comming Soon
We do protein A/G purification from ascites.
Pricing: PDF Version ![]()